نبذة مختصرة : The paper presents results of an investigation of efficacy and safety of using the NMDA receptor antagonist Akatinol-Memantine in the treatment of moderate and severe Alzheimer dementia. An open comparative investigation was performed in two patient groups: group I (N=30) received Akatinol-Memantine, while group II (N=25) did not receive this pathogenetic treatment. Akatinol-Memantine was prescribed in dose 20 mg/ day during 26 weeks. The groups matched on clinical characteristics (clinical form of Alzheimer disease, severity of dementia), psychometric parameters (average group measures on MMSE and PSMS Scales before investigation) and demographic characteristics (mean age, sex). The results of this investigation showed that a 6-month treatment with Akatinol-Memantine significantly improved cognitive functions and self-care of the patients, produced a decrease of some behavioral and psychotic disorders, such as agitation and aggression, depression and anxiety, irritability and aberrant motor activities, and significantly reduced (by 26.8%) the burden of stress on care providers. In control group, cognitive impairment increased significantly while self-care deteriorated. Behavioral and psychotic symptoms diminished insignificantly and the stress burden for care providers was 3.3 times less obvious. Adverse phenomena like vegetative-vascular crises, elements of aggression and false perceptions were registered in single cases; they were mild and responded fast to symptomatic medication. Conclusion: A six-month course of treatment with Akatinol-Memantine reduced significantly the symptoms of cognitive impairment and significantly improved self-care; it significantly changed for the better the severity of some behavioral and psychotic disorders and also significantly relieved the stress burden of care providers. The group free of pathogenetic treatment demonstrated within six months a significant deterioration of cognitive impairment as well as self-care skills, while the reduction of some behavioral and psychotic ...
Processing Request
No Comments.